Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: A prospective study

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Rajenderan, Sangeetha ^a   Balaji, Veeraraghavan ^a   Anandan, Shalini ^a   Sahni, Rani Diana ^a   Tansarli, Giannoula S ^b   Falagas, Matthew E ^b,c,d  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BIAPENEM; CARBAPENEM DERIVATIVE; CEFMETAZOLE; CEFMINOX; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; DORIPENEM; FOSFOMYCIN; GENTAMICIN; HABEKACIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; ANTIINFECTIVE AGENT; CEPHAMYCIN DERIVATIVE; DIBEKACIN; THIENAMYCIN DERIVATIVE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD SAMPLING; BROTH DILUTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GROWTH INHIBITION; IN VITRO STUDY; INDIA; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SPUTUM CULTURE; TERTIARY CARE CENTER; URINALYSIS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GRAM NEGATIVE INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; CEPHAMYCINS; DIBEKACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FOSFOMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INDIA; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 84904880487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103253     Document Type: Article

References (41)

1. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, et al. (2009) Characterization of a new metallo-beta-lactamase gene, bla (NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53: 5046-5054.
2. Gupta N, Limbago BM, Patel JB, Kallen AJ (2011) Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53: 60-67.
3. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, et al. (2012) Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 18: 54-60.
4. Chang HJ, Hsu PC, Yang CC, Kuo AJ, Chia JH, et al. (2011) Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect 44: 125-130.
5. Amudhan SM, Sekar U, Arunagiri K, Sekar B (2011) OXA beta-lactamase- mediated carbapenem resistance in Acinetobacter baumannii. Indian J Med Microbiol 29: 269-274.
6. De AS, Kumar SH, Baveja SM (2010) Prevalence of metallo-beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter species in intensive care areas in a tertiary care hospital. Indian J Crit Care Med 14: 217-219.
7. Sinha N, Agarwal J, Srivastava S, Singh M (2013) Analysis of carbapenem-resistant Acinetobacter from a tertiary care setting in North India. Indian J Med Microbiol 31: 60-63.
8. Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J (2008) Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients. Indian J Med Res 127: 398-402.
9. Abhilash KP, Veeraraghavan B, Abraham OC (2010) Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in south India. J Assoc Physicians India 58 Suppl: 13-17.
10. Anandan S, Thomas N, Veeraraghavan B, Jana AK (2009) Prevalence of extended- spectrum beta-lactamase producing Escherichia coli and Klebsiella spp in a neonatal intensive care unit. Indian Pediatr 46: 1106-1107.
11. Chaudhuri BN, Rodrigues C, Balaji V, Iyer R, Sekar U, et al. (2011) Incidence of ESBL producers amongst Gram-negative bacilli isolated from intra-abdominal infections across India (based on SMART study, 2007 data). J Assoc Physicians India 59: 287-292.
12. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, et al. (2012) The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis 31: 1663-1666.
13. Hamada Y, Tamura K, Koyama I, Kuroyama M, Yago K, et al. (2011) Clinical efficacy of arbekacin for Gram-negative bacteria. J Infect Chemother 17: 876-879.
14. Araoka H, Baba M, Tateda K, Ishii Y, Oguri T, et al. (2012) In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan. Jpn J Infect Dis 65: 84-87.
15. Hoellman DB, Spangler SK, Jacobs MR, Appelbaum PC (1998) In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds. Antimicrob Agents Chemother 42: 495-501. (Pubitemid 28114798)
16. Lerma M, Cebrian L, Gimenez M, Coronel P, Gimeno M, et al. (2008) beta-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes. Rev Esp Quimioter 21: 149-152.
17. Appelbaum PC, Spangler SK, Jacobs MR (1993) Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 32: 223-231. (Pubitemid 23272307)
18. Aldridge KE, Morice N, Schiro DD (1994) In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 38: 889-893. (Pubitemid 24114040)
19. Abe N, Komatsu M, Iwasaki M, Nagasaka Y, Fukuda S, et al. (2005) [In vitro activity of antimicrobial agents against clinical isolates of Pseudomonas aeruginosa]. Jpn J Antibiot 58: 445-451.
20. Livermore DM, Mushtaq S (2013) Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 68: 1825-1831.
21. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, et al. (2010) Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 16: 184-186.
22. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, et al. (2007) Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 29: 62-65. (Pubitemid 44959781)
23. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, et al. (2010) Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 22: 355-357.
24. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE (2010) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10: 43-50.
25. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE (2009) Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 18: 921-944.
26. Winn W, Allen S, Janda W, Koneman E, Procop G, et al. (2006) Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th edition". The Enterobacteriaceae. Chapter 6, s.213-293, Lippincott Williams&Wilkins, Baltimore, USA.
27. Winn W, Allen S, Janda W, Koneman E, Procop G, et al. (2006) Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th edition". The Nonfermentative Gram-negative Bacilli. Chapter 7, s.309-355, Lippincott Williams&Wilkins, Baltimore, USA.
28. (2012) Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Wayne, PA, USA.
29. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL (2012) 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 25: 626-633.
30. Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, et al. (2010) In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. Antimicrob Agents Chemother 54: 3015-3017.
31. Sahni RD, Balaji V, Varghese R, John J, Tansarli GS, et al. (2013) Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiol (in press).
32. Falagas ME, Karageorgopoulos DE, Nordmann P (2011) Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol 6: 653-666.
33. Maraki S, Mavros MN, Kofteridis DP, Samonis G, Falagas ME (2012) Epidemiology and antimicrobial sensitivities of 536 multi-drug-resistant gram-negative bacilli isolated from patients treated on surgical wards. Surg Infect (Larchmt) 13: 326-331.
34. Somily AM, Absar MM, Arshad MZ, Al Aska AI, Shakoor ZA, et al. (2012) Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline. Saudi Med J 33: 750-755.
35. Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, et al. (2011) Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 50: 1009-1013.
36. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, et al. (2010) Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35: 194-199.
37. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME (2005) Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11: 115-121. (Pubitemid 40259694)
38. Behera B, Das A, Mathur P, Kapil A, Gadepalli R, et al. (2009) Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res 129: 446-450.
39. Gladstone P, Rajendran P, Brahmadathan KN (2005) Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care units. Indian J Med Microbiol 23: 189-191. (Pubitemid 41188495)
40. Sinha M, Srinivasa H, Macaden R (2007) Antibiotic resistance profile & extended spectrum beta-lactamase (ESBL) production in Acinetobacter species. Indian J Med Res 126: 63-67. (Pubitemid 350020550)
41. Taneja N, Singh G, Singh M, Sharma M (2011) Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res 133: 681-684.